1Ragini K, Rush M, O'Regan A. Aromatase inhibitors as adjuvant therapy for postmenopansal patients with early stage breast cancer[J].Cancer J Clin, 2005,55:145-163.
2Brian J L, Danijela J, Venkatesh H,et al. Therapeutic s trategie susing the aromatase inhibitor retrozole and tamoxifen in a breastc ancer model[J]. J Natl Cancer Inst,2004,96:456-465.
3Mouridsen H, Chaudri-Ross H A. Breast cancer efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer [J]. The Oncologist,2004,9:497-506.
4Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized,cross-over study[J]. J Clin Oncol,2002,20:751-757.
5Moufidsen H, Gershanovich M, Sun Y, et al. Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International letrozole Breast Cancer Group[J]. J Clinical Oncol,2003,21:2101-2109.
6Paul E G, James N I, Silvana M,et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in re ceptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst,2005,97:1262-1271.
